Lenvatinib has been demonstrated to decrease PD-L1 expression in HCC and inhibit the differentiation of regulatory regulatory T cells (Tregs) through the blockade of FGFR-4. This evidence concerns the gene FGFR4 and hepatocellular carcinoma.